Designation of Fomepizole (TBA) as an orphan drug by AFT Pharmaceuticals

Overview

The Therapeutic Goods Act 1989 was enacted to provide a comprehensive regulatory framework for therapeutic goods in Australia, ensuring that these goods are safe, of high quality, and effective. A specific problem the Act was designed to address includes the availability and development of treatments for rare and life-threatening conditions, which often do not attract significant investment from the pharmaceutical industry due to their low prevalence. To fill this gap, the Act includes provisions for the designation of orphan drugs, which are medications developed to treat rare diseases or conditions. This legislative measure aims to encourage the development and availability of treatments for conditions that might otherwise be neglected. The Therapeutic Goods Act 1989 is administered by the Therapeutic Goods Administration, a division of the Department of Health, and the policy objective is to facilitate access to orphan drugs that are critical for the treatment of rare and serious conditions, thereby improving health outcomes for affected individuals.

Scope and Application

The Therapeutic Goods Act 1989, as applied through this specific designation, pertains to Fomepizole (TBA), a therapeutic product designated as an orphan drug for the treatment of ethylene glycol and methanol poisonings. This Act, administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia, applies to the designated drug and its sponsor, AFT Pharmaceuticals Pty Ltd. The orphan drug designation under this Act is intended for medications that address rare medical conditions, which in this case are severe poisonings caused by ethylene glycol and methanol. The legislation's jurisdictional reach is national, aligning with the overarching framework of the Therapeutic Goods Act 1989, which governs therapeutic goods across Australia. This Act does not explicitly state exclusions or exemptions but is subject to the broader regulatory stipulations and requirements of the Therapeutic Goods Regulations 1990. The scope of application may be further refined or extended through subordinate instruments issued by the TGA.

Key Provisions

The key provision of this legislation is the designation of Fomepizole (TBA) as an orphan drug for the treatment of ethylene glycol and methanol poisonings, as per Section 16J of the Therapeutic Goods Regulations 1990 (subsection 16J(2)). This designation recognises the need for special incentives to develop treatments for rare diseases, where the patient population is too small to be commercially viable without such support. This designation is effective from 6 January 2015, and the specific dose form for this indication is an injection. The sponsor for Fomepizole (TBA) is AFT Pharmaceuticals Pty Ltd, who will be responsible for the drug's development and compliance with the regulations. The obligations imposed by this designation include ensuring that Fomepizole (TBA) meets all safety, efficacy, and quality standards as stipulated by the Therapeutic Goods Act 1989 and its Regulations. The sponsor must also comply with any additional requirements set forth by the Therapeutic Goods Administration (TGA) regarding the orphan drug designation. This includes providing the TGA with necessary information and documentation to support the orphan drug status and ensuring that the drug is manufactured and distributed in accordance with the regulations. Breach of the obligations and requirements under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can lead to significant consequences. Offences under the Act may include the unauthorised use of the orphan drug designation, failure to provide accurate information to the TGA, or non-compliance with safety and quality standards. The penalties for such breaches can be substantial and may include fines, imprisonment, or both, depending on the severity of the offence. For example, serious or repeated breaches may result in penalties up to $1.1 million for a corporation and $220,000 for an individual, as well as potential criminal charges. Additionally, the TGA has the authority to suspend or cancel the registration of the therapeutic goods in question, which could severely impact the availability of the designated orphan drug.